261 related articles for article (PubMed ID: 24973373)
1. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Sugrue D; Bogner R; Ehret MJ
Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
[TBL] [Abstract][Full Text] [Related]
2. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Pheils J; Ehret MJ
Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
[TBL] [Abstract][Full Text] [Related]
3. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Moen MD; Keam SJ
CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
[TBL] [Abstract][Full Text] [Related]
4. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
[TBL] [Abstract][Full Text] [Related]
5. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
6. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
7. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
Robinson DM; Keating GM
Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
[TBL] [Abstract][Full Text] [Related]
8. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
McGough JJ; Pataki CS; Suddath R
Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
[TBL] [Abstract][Full Text] [Related]
10. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
12. Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.
Kowalik S; Minami H; Silva R
Expert Opin Pharmacother; 2006 Dec; 7(18):2547-57. PubMed ID: 17150008
[TBL] [Abstract][Full Text] [Related]
13. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Brams M; Mao AR; Childress A; Wang J
J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
[TBL] [Abstract][Full Text] [Related]
14. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
[TBL] [Abstract][Full Text] [Related]
15. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
[TBL] [Abstract][Full Text] [Related]
16. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
[TBL] [Abstract][Full Text] [Related]
17. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
18. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
[TBL] [Abstract][Full Text] [Related]
19. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
Quinn D
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
Childress AC; Spencer T; Lopez F; Gerstner O; Thulasiraman A; Muniz R; Post A
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):351-61. PubMed ID: 19702487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
